血清胸苷激酶1与急性髓系白血病的相关性分析  

Analysis of Correlation between Serum Thymidine Kinase 1 and Acute Myeloid Leukemia

作　　者：王婷敬[1] 孙爱宁[1] 吴德沛[1] 李渭阳[1] 梁建英[1] 

机构地区：[1]苏州大学附属第一医院血液科江苏省血液研究所,卫生部血栓与止血重点实验室,江苏苏州215006

出　　处：《中国实验血液学杂志》2013年第5期1095-1098,共4页Journal of Experimental Hematology

基　　金：江苏省临床医学科技专项(编号BL2012005)资助项目;江苏省科教兴卫工程-临床医学中心(编号ZX201102)资助项目

摘　　要：本研究探讨血清胸苷激酶1(TK1)的水平变化在急性髓系白血病(AML)中的临床意义。采用ECL印迹免疫增强发光法分别检测60例初诊AML患者诱导化疗前、化疗结束二周及巩固期外周血血清TK1浓度,采用非参数检验分析组间差异,收集60例AML患者的临床与实验室检查资料。结果表明,在60例AML中,获得缓解(完全缓解和部分缓解)患者的血清TK1浓度与治疗前相比均有不同程度的降低(P<0.05),而未缓解者则无明显变化(P>0.05);处于完全缓解的AML患者血清TK1水平持续低表达,本病复发后则显著升高(P<0.05)。TK1浓度与染色体核型、血清乳酸脱氢酶(LDH)水平、初诊时是否伴有发热之间均存在一定的相关性(P<0.05)。结论:监测血清TK1水平变化在AML的临床诊治、疗效监测、预后评估以及复发风险提示方面具有一定的参考价值:TK1浓度降低提示治疗有效和肿瘤负荷减低,TK1浓度升高则提示预后欠佳和有复发风险。This study was purposed to investigate the clinical significance of serum thymidine kinase 1 （ STK1 ） level change in acute myeloid leukemia（AML）. Peripheral blood samples of 60 newly diagnosed AML patients were collected and the STK1 levels were determined by enhanced chemiluminescent dot-blot method before and at two weeks after start of inductive treatment and in consolidatory treatment. Using non-parametric test, the differences between groups were analyzed. Then the correlation between STK1 level and clinical characteristics was explored by a way of chi-square test. The results indicated that the serum TK1 level in complete remission（CR） or partial remission（PR） AML patients de- creased in varying degree as compared to pretreatment（ P 〈 0.05 ）, while there was no significant difference of TK1 level in non-remission（NR） ones（P 〉 0.05）. The serum TK1 level in CR patients remained low level but increased noticea- bly after relapse into progressive disease（P 〈 0.05 ）, A significant correlation was found between STK1 level and chro- mosomal abnormalities, serum LDH level as well as whether had fever in de novo AML patients （ P 〈 0.05）. It is con- cluded that the serum TK1 level change may be applied for reflecting the aggressiveness of disease, monitoring the clini- cal response to chemotherapy, evaluating the prognosis and predicating the relapse risk. The decrease of TK1 level sug- gests effective treatment and tumor burden reduction, while its increase indicate poor prognosis and relapse risk.

关 键 词：急性髓系白血病 血清胸苷激酶1 细胞增殖标志物 

分 类 号：R733.71[医药卫生—肿瘤]